Novo Nordisk says obesity drug trial confirms weight lossCOPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss. "These data, together with previously reported Phase III trials, consistently demonstrate clinically significant weight loss and improvements in obesity-related risk factors in people with obesity," chief science officer Mads Krogsgaard Thomsen said in the statement. Just how big the product could be is fiercely debated by analysts. ...
Source: Novo Nordisk says obesity drug trial confirms weight loss (http://news.yahoo.com/novo-nordisk-says-obesity-drug-trial-confirms-weight-165745705.html)